Testing a new drug for agitation in Alzheimer's disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Alzheimer's disease (confirmed by a biomarker test).
- You have had significant agitation or aggression for at least the past 4 weeks.
- Your score on a memory test (MMSE-1) is 24 or lower.
- You are able to walk on your own or with a walker or wheelchair.
- You live in a stable home, assisted living, or nursing home, and a caregiver can join you if you live at home.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a study medicine to reduce “agitation” behaviors in people with Alzheimer’s dementia. You and your caregiver would complete required assessments and may need genetic and blood testing to check how the body handles the drug.
This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.
This Phase 3 trial studies whether nabilone can reduce agitation (restlessness, anger, or difficult behavior) in people with Alzheimer’s dementia. It’s designed for older adults who already have agitation despite standard dementia care.
This study tests if a CBD medication can help reduce agitation in people with Alzheimer's disease. It's for adults 55 and older who have significant agitation and mild to moderate dementia.
This trial studies treatment for troubling nighttime restlessness and agitation in people with Alzheimer’s disease. It may help improve sleep and nighttime comfort and reduce nighttime behavior problems.
This trial tests a skin patch that delivers a medicine called dexmedetomidine to help calm agitation in people with Alzheimer's disease. It might be an option for those living in a care facility who have had recent episodes of agitation.
Hear when a new Agitation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.